Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10327996" target="_blank" >RIV/00064203:_____/16:10327996 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/16:10327996

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s00277-016-2731-x" target="_blank" >http://dx.doi.org/10.1007/s00277-016-2731-x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00277-016-2731-x" target="_blank" >10.1007/s00277-016-2731-x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia

Popis výsledku v původním jazyce

Recent studies in adult lymphoma patients have indicated a correlation between polymorphisms of Fc gamma-receptors (Fc gamma Rs, encoded by the respective FCGR genes) and the response to rituximab treatment. In vitro, cells expressing Fc gamma RIIIa-158V mediate antibody-dependent cellular cytotoxicity (ADCC) more efficiently than cells expressing Fc gamma RIIIa-158F. The impact of the FCGR2A-131HR polymorphism is unclear. In this study, the FCGR polymorphisms FCGR3A-158VF and FCGR2A-131HR were analyzed in pediatric patients with mature aggressive B cell non-Hodgkin lymphoma/leukemia (B-NHL). Pediatric patients received a single dose of rituximab monotherapy. Response was evaluated on day 5 followed by standard chemotherapy for B-NHL. Among 105 evaluable patients, a response to rituximab was observed in 21 % of those homozygous for Fc gamma RIIa-131RR (5/24) compared to 48 % of patients who were HH and HR Fc gamma RIIa-131 allele carriers (18/34 and 21/47, respectively; p = 0.044). Among patients with the FCGR3A-158 polymorphism, those homozygous for the FF genotype had a significantly favorable rituximab response rate of 59 % (22/37) compared to 32 % in patients who were Fc gamma RIIIa-158VV and Fc gamma RIIIa-VF allele carriers (2/9 and 20/59, respectively; p = 0.022). A stringent phase II response evaluation of children and adolescents with B-NHL after one dose of rituximab monotherapy showed a significant association between the rituximab response rate and FCGR polymorphisms. These findings support the hypothesis that FCGR polymorphisms represent patient-specific parameters that influence the response to rituximab.

Název v anglickém jazyce

Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia

Popis výsledku anglicky

Recent studies in adult lymphoma patients have indicated a correlation between polymorphisms of Fc gamma-receptors (Fc gamma Rs, encoded by the respective FCGR genes) and the response to rituximab treatment. In vitro, cells expressing Fc gamma RIIIa-158V mediate antibody-dependent cellular cytotoxicity (ADCC) more efficiently than cells expressing Fc gamma RIIIa-158F. The impact of the FCGR2A-131HR polymorphism is unclear. In this study, the FCGR polymorphisms FCGR3A-158VF and FCGR2A-131HR were analyzed in pediatric patients with mature aggressive B cell non-Hodgkin lymphoma/leukemia (B-NHL). Pediatric patients received a single dose of rituximab monotherapy. Response was evaluated on day 5 followed by standard chemotherapy for B-NHL. Among 105 evaluable patients, a response to rituximab was observed in 21 % of those homozygous for Fc gamma RIIa-131RR (5/24) compared to 48 % of patients who were HH and HR Fc gamma RIIa-131 allele carriers (18/34 and 21/47, respectively; p = 0.044). Among patients with the FCGR3A-158 polymorphism, those homozygous for the FF genotype had a significantly favorable rituximab response rate of 59 % (22/37) compared to 32 % in patients who were Fc gamma RIIIa-158VV and Fc gamma RIIIa-VF allele carriers (2/9 and 20/59, respectively; p = 0.022). A stringent phase II response evaluation of children and adolescents with B-NHL after one dose of rituximab monotherapy showed a significant association between the rituximab response rate and FCGR polymorphisms. These findings support the hypothesis that FCGR polymorphisms represent patient-specific parameters that influence the response to rituximab.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of Hematology

ISSN

0939-5555

e-ISSN

—

Svazek periodika

95

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

10

Strana od-do

1503-1512

Kód UT WoS článku

000381113700012

EID výsledku v databázi Scopus

2-s2.0-84976897446